Jacksoneye First in the Midwest to Offer Avellino DNA Dual Test for LASIK Safety

Slide background
Slide background
Slide background
Slide background
Slide backgroundSlide thumbnail
Slide background
Slide background
Slide background
Slide background
Slide background
Slide background
Slide background
Slide background

Avellino Lab USA’s Genetic Test Makes LASIK Safer for the 350,000 Patients Who Undergo the Procedure Each Year

Lake Villa, Ill. – 08/06/2014 – Jacksoneye, a leading-edge center of ophthalmic innovation and technology, today announced its partnership with Avellino Lab USA, developer of the only genetic test available worldwide for Granular Corneal Dystrophy (GCD), a disease that can eventually lead to complete loss of vision. For over twenty years, Jacksoneye, founded by leading ophthalmologist Dr. Mitch Jackson, has been dedicated to continuously improving patient care and implementing innovative procedures to restore vision. Having performed more than 32,000 LASIK surgeries since 1993, Dr. Jackson is one of the leaders in the ophthalmic industry, specializing in LASIK, cataract lens replacement, laser-assisted cataract surgery, contact lens implant, corneal transplant and specialized glaucoma treatment. Now, Jacksoneye will be offering the Avellino DNA Dual Test for LASIK Safety for its LASIK patients to further increase patient safety and success.

Avellino Lab USA, a Clinical Laboratory Improvement Amendments (CLIA) certified molecular diagnostic testing lab, was launched in March 2013 and is based in Menlo Park, California. The Avellino DNA Dual Test was developed to detect Granular Corneal Dystrophy type 1 (GCD1) and type 2 (GCD2), a disease that causes cloudiness, specifically grey-white granular protein deposits on the corneas, which can lead to loss of clear vision. GCD has been diagnosed in patients throughout the world and is one of the more well-known corneal dystrophies related to genetic mutations. While GCD usually develops slowly, carriers of this genetic mutation are at an extremely high risk of accelerated opacity formations should they undergo vision-correction surgery such as LASIK, LASEK or PRK. Fortunately, the Avellino DNA Dual Test positively identifies, with high accuracy, if a person has the genetic mutation. By doing so, the test reduces the risk of patients with the GCD mutation having post-LASIK vision impairment and increases their confidence that they are avoiding unnecessary harm to their vision.

“After having performed more than 30,000 Laser Vision Correction procedures (LASIK, PRK, LASEK), any risk that can be detected prior to the procedure to prevent a sight-threatening complication is critical. By implementing the newest simple cheek swab test to detect for Granular Corneal Dystrophy, Jacksoneye is providing the safest and most consistent visual outcome possible. All LASIK and/or PRK patients will undergo this new simple effective test prior to surgery to assure the safest outcome possible,” said Dr. Jackson.

The Avellino DNA Dual Test is easy and safe. The test involves a simple mouth swab to determine whether a person carries the GCD1 or the GCD2 gene mutation. Specifically, the ophthalmologist takes 10 swipes from the inside of each cheek in order to obtain an adequate sample. The sample is then sent to Avellino Lab USA, and within 24 to 48 hours, the results are provided to the Jacksoneye physician to share with the patient. Based on a negative result, patients are able to proceed with the planned LASIK procedure with confidence. If an individual is identified as positive for the genetic mutation, he or she will be advised against having LASIK surgery and encouraged to take protective measures, such as minimizing exposure to UV light by wearing appropriate protective lenses to help postpone the progression of GCD symptoms.

“Jacksoneye’s adoption of the Avellino DNA Dual Test truly emphasizes their continuous commitment to delivering state-of-the-art technology to their patients,” said Scott Korney, COO of Avellino Lab USA. “By partnering with respected laser vision clinics such as Jacksoneye, Avellino Lab USA continues to make eye correction surgery safer for patients throughout the country.”

About Jacksoneye

For 21 years, Jacksoneye has been providing the Lake Villa, Illinois community with quality eye care. The clinic is led by Dr. Mitch Jackson, a board-certified ophthalmologist, who has performed over 30,000 LASIK surgeries and over 20,000 cataract surgeries since 1993. Dr. Jackson’s specialty is offering personalized lifestyle assessment and advanced options in cataract lens replacement, LASIK, implantable contact lens replacement, corneal transplant and specialized glaucoma care. Combining patient-centered care with innovative procedures, Jacksoneye aims to provide patients with a personal, family-centered experience.

About Avellino Lab USA

Avellino Lab USA has developed the first and only commercially available testing system, the Avellino DNA Dual Test for LASIK Safety, for Granular Corneal Dystrophy type 1 (GCD1) and Granular Corneal Dystrophy type 2 (GCD2), also known as Avellino Corneal Dystrophy (ACD). The company’s proprietary genetic diagnostics system provides fast, safe and affordable evaluations of an individual’s genetic predisposition to GCD1 and/or GCD2. With the Avellino DNA Dual Test, Avellino Lab USA is able to positively identify, with high accuracy, a patient’s GCD status. Based on the test’s results, patients and their physician can make an informed decision when considering vision correction surgery.

Media Contact:
Brianne Cannon
MSLGROUP
415-512-0770
avellinolab@mslgroup.com